Clinical Trial: AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07158840) titled 'AK112 in Non-squamous Non-small Cell Lung Cancer (NSCLC)Patients With Actionable Genomic Alterations (AGA) Who Have Failed to Previous Tyrosine Kinase Inhibitor (TKI) Treatment' on Aug. 14.

Brief Summary: AK112 in non-squamous non-small cell lung cancer patients with actionable genomic alterations (AGA) who have failed to previous tyrosine kinase inhibitor (TKI) treatment

Study Start Date: Sept. 05

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: AK112

AK112 Monotherapy

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Akeso

Published by HT Digital Content Services with permission from Hea...